Xenotransplantation : an honors thesis (HONRS 499) by Baumgartner, Heidi K.
Xenotransplantation 
An Honors Thesis (HONRS 499) 
by 
Heidi Kay Baumgartner 
Thesis Advisor 
Dr. Nancy Behforouz 
Ball State University 
Muncie, Indiana 
April 1997 
Expected Date of Graduation 
May 1997 
r- , 
19 C) '1' 
1 ..- I 
V -, () 
, J- ĤŸHĚ() 
This is a presentation on xenotransplantation, which is the transfer of organs or 
tissue between two different species, This area of scientific research is making significant 
headway in the world of transplantation and may save thousands of lives in the near future. 
An explanation of what xenotransplantation is and what it must overcome in order to be 
successful is the starting point of this discussion, Following this introduction, is a 
discussion of the latest research in xenotransplantation and the knowledge gained through 
each study. The concerns of the risks involved are also addressed with varying views of 
where xenotransplantation is headed. In the hopes of reducing risks and allowing the 
research for cross-species transplantation to continue, the presentation ends with the 
regulations set forth by the Public Health Service. 
-Xenotransplantation 
Due to the advancements in medical research and technology, organ 
transplantation has become an accepted and successful practice. The latest technology has 
come so far that there are tens of thousands of people in the United States every year 
waiting for new and healthy organs. The biggest problem faced by these people in need 
and by transplantation surgeons nation wide is that there are not enough human organ 
donors available. In 1996, there were 33,000 people in need of an organ transplant and 
nearly 3,000 of them died because there were simply not enough donor organs (Benowitz 
1996). In an attempt to find a solution to this shortage, research scientists have looked 
into a different kind of donor for tansplantation, one of a different species than the Homo 
sapien. Xenotransplantation, the transplantation of tissue or organs between different 
species, has gained a new importance in medicine today and has made some major leaps in 
the last three years. Although there has not been a successful xenotransplant yet, 
immunologists have made significant headway in understanding what is involved in 
xenotransplant rejection and survival and the risks involved in transplanting tissue or 
organs from one animal to another. 
Much like dealing with allograft transplantation (transplantation between the same 
species), xenotransplantation must overcome rejection. Hyperacute and acute rejection 
are two important processes involved in destroying a transplanted organ. Hyperacute 
rejection occurs over the short period of time of a few minutes to a few hours and involves 
the destruction of the transplanted organ by preformed antibodies in the recipient to the 
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donor's antigens that activate the complement system. This complement system causes 
the activation of platelets, thrombosis, endothelial injury and fibrinoid necrosis that leads 
to rejection (Benjamini 1996). In hyperacute xenograft rejection, endothelial 
glycoproteins have been identified as targets of these antibodies and complement. 
Specifically, the alpha-galactosyl epitope expressed on the cell surfaces of all mammals 
excluding the Old World Primates has been observed (Rother 1996). The Old World 
Primates have anti-Gal that recognize the xenoantigen of alpha-galactosyl and creates a 
natural immunity by activating the complement system. Acute rejection, unlike the 
humoral immune response of hyperacute rejection, is a cell mediated immune response 
involving T -cells. This form of rejection includes a heavy infiltration of lymphocytes and 
macrophages into the transplanted organ that eventually destroy it. This is often seen 
when the donor recipient has not been previously sensitized to the transplanted organ 
(Benjamini 1996). 
Included in the rejection ofxenotransplants are the different types of animals 
involved in the transplant. How closely the animals are genetically related plays a critical 
role in the response of the host and donor to each other. There are two basic types of 
xenotransplants. Those of concordant type are transplants of organs between species that 
are closely related. The rejection observed in this type of xenotransplant is not as dramatic 
or as fast as rejection seen with more distantly related species. Concordant 
xenotransplantation can be further divided into easy and difficult transplants according to 
rejection process severity. Rejection during easy concordant xenotransplantation is similar 
to rejections seen in allograft transplantation. The most important antigens causing 
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-destruction of the organ are histocompatibility antigens and specific xenoantigens present 
of the organ. Difficult concordant xenotransplantation shows the most significant antigens 
are the glycoproteins that have the alpha-galactosyl epitope. Large amounts of antibodies 
are produced by the host in response to the xenoantigen and rejection occurs after a few 
days. The other type ofxenotransplantation, discordant transplantation, involves species 
that are not closely related genetically. This form of rejection occurs within minute to a 
few hours and it is extremely dramatic. The activation of the classical and the alternative 
pathways of complement are the major components of this form of rejection. 
Each of these types of xenotransplantation has particular obstacles to overcome in 
order to stop rejection from occurring. Easy concordant xenorejection can be interrupted 
by immunosuppressive drugs such as cyclosporin and other anti-proliferative substances 
(Kemp 1996). Difficult concordant xenorejection has been shown to be reduced by the 
use of immunosuppressive substances aimed at prevention of newly formed or possible 
future xenoantibodies from being formed. Such substances include cyclosporin, FK-506, 
leflunomide, rapamycin, brequinar sodium, cyclphosphamide or cobra venom factor 
(Kemp 1996). Discordant xenorejection can be blocked by inactivating the complement 
system and/or by using transgenic animals with a complement system that has been 
altered. Complement can be inactivated by using soluble complement receptor type 1 
(SCR 1) which becomes bound to and inactivates the C3 and C5 convertases of the 
classical and alternative complement pathways (Bollinger 1996). In transgenic animals, 
the human regulatory proteins ofDAF, MCR and CD59 of complement are incorporated 
into the donor animal for resistance to hyperacute rejection (Bollinger 1996). 
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Not only is understanding the mechanisms involved in the different types of 
xenotransplantation rejection important, but other factors become critical in determining 
what animals are the best suited for transplantation. Concordant xenotransplantation may 
be easier to control, but it has many disadvantages. Animals that are more closely related 
to humans, such as chimpanzees, are not available in large numbers, they are slow to 
reproduce, and may carry pathogens that could infect humans. Discordant 
xenotransplantation may be more difficult to control, but it has many advantages. Animals 
that are not closely related to humans genetically such as pigs are available in large 
numbers, they come in different sizes, they reproduce quickly, and they have only a small 
number of pathogens that could infect humans. Pigs can also be easily manipulated 
through genetic engineering (Bollinger 1996). 
Considering hyperacute and acute rejection, concordant and discordant species, 
and humoral and cell mediated immune responses, researchers have devoted much time 
and energy to find a way to succeed in xenotransplantation. Within the past three years 
significant progress has been made through the study of several different types of 
xenotransplantation attempts. Important combinations of animals that have been key to 
better understanding this cross-species transplantation are pig-baboon, guinea pig-rat, 
human-rat, pig-dog, human-mouse, rat-mouse, human-baboon, and hamster-rat. 
In the study of xenotransplantation between pigs to baboons, several key 
mechanisms for rejection were examined as well as possible methods to prevent it were 
explored. In one study, researchers used pigs and baboons to examine naturally produced 
antibodies specific for xenoantigens (Bailey 1994). These antibodies are responsible for 
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activation of the complement system which leads to hyperacute rejection. Pig hearts were 
transplanted into baboons and the natural antibodies produced against pig white blood 
cells, pig red blood cells, and pig endothelial cells were to be measured and observed for 
their role in the hyperacute rejection. The researchers attempted to stop these antibodies 
from promoting the complement cascade by several methods. They attempted to adsorb 
the baboon's natural antibody from several organs of the baboon. The pig heart in the 
baboon showed prolonged survival with the antibody absorption (Bailey 1994). The 
scientists also attempted to decrease the natural anti-pig antibody in the baboon by 
performing a cardiopulmonary bypass which dilutes the blood. Dilution of the blood was 
successful at reducing the anti-pig antibodies found in the baboon and indicates that the 
decreasing of the anti-pig antibodies against red blood cells could contribute to the 
prolonged survival of the pig heart in the baboon . 
Pigs and baboons have also been used to study the idea of possibly using 
xenotransplantation as a means of keeping someone alive until a proper allograft is 
available. The idea of using cross-species organs as a bridge brought up the question of 
whether or not using a xenograft first would increase the chances of quicker cellular 
rejection as well as humoral rejection due to the sensitization of the recipient by the 
xenograft. In this study they tested baboons by first transplanting a pig heart into the 
baboon and then following the xenotransplant with an allografted transplant (Baker 1995). 
The survival of these allografts were observed. The results of this research showed that 
the primary pig heart in the baboon did not lead to the sensitization of the baboon to the 
secondary baboon heart. The allografts appeared to functional as normal and there was no 
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indication of hyperacute rejection or cellular rejection of the transplanted heart. 
The combination of guinea pig and rat in xenotransplantation models has also lead 
to the further understanding of rejection and the possibility of inhibiting of it. There has 
been a study with these two animals to explore the part that phosphatidic acid plays in 
xenotransplant rejection. Phosphotidic acids playa key part in intracellular signaling and 
are observed to be activated at the time of the inflammation response. The chemical 
substance oflisofylline acts to inhibit this critical role of phosphatidic acid and thus slows 
down or stops the inflammatory response. In this study, guinea pig hearts were 
transplanted into rats. Two particular drugs were tested to see if they could inhibit the 
inflammation caused in xenotransplant rejection by stopping the activation of phosphatidic 
acid. The drug of methyprednisolone (MPS), which is a steroid, had a small effect on the 
prolonging of the survival of the guinea pig heart in the rat (Fung 1996). Lisofylline used 
by itself had a larger effect on the survival of the heart than the MPS, but the two drugs 
used together in this study showed a significant increase in the length of survival of the 
transplanted organ (Fung 1996). 
Another study using guinea pigs and rats that contributed to the better understand 
of long-term survival ofxenotransplants in animals distantly related, genetically. In this 
study, splenocytes were tested to see how they were involved in the hyperacute rejection 
ofxenotransplantation. The splenocytes of guinea pigs were injected into the spleens of 
rats. Certain immunosuppressive drugs were used to test for their effect on the prevention 
of rejection. It was observed that the splenocytes of the guinea pig were responsible for 
activating both B cell and T cells of the rat's immune response. The research team found 
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-cyclophosphamide and FK 506 to be successful chemical substances that act to decrease 
the activation ofT cell and thus able to prolong the survival ofxenografts (Hayashi 1994). 
Guinea pigs and rats have also been used to explore the effects of particular 
synthetic drugs on the rejection of discordant xenotransplants. The drugs used in this case 
were sulfated oligosaccharides types A and B. They were tested to find their possible role 
in the inhibition of endothelial cell activation which is a major component in the 
hyperacute rejection process. The exposure to these oligo saccharides just before 
revascularization led to an increased length of the xenograft survival. The saccharides 
were observed to prevent the release of hepar an sulfate from the cardiac endothelial cells 
of the guinea pig that would normally be induced by the rat serum (Buler 1996). This 
heparan sulfate is located on the surface of endothelial cells and plays a significant role in 
many of the physiological properties of the blood vessels such as preventing thrombotic 
cell surfaces, injury from oxidants, and the flow of plasma proteins and bloods cells out of 
the vessels (Buler 1996). In the process of hyperacute rejection, antibodies (IgM) bind to 
the endothelial cells and this interaction activates complement. This activation of 
complement in tum causes heparan sulfate to be released, causing the major features ofthe 
pathological rejection. Both oligo saccharides A and B were observed to prolong the life 
of the xenograft between two distantly related species. This can be an important 
advancement in other xenotransplants as well. Oligosaccharide A has been observed to 
inhibit the heparan sulfate release in humans also (Buler 1996). 
Human to rat xenotransplantations have also been important in the building 
knowledge of this transplantation. In one study using humans and rats, the possibility of 
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the induction of tolerance to foreign cells was determined. Knowing that the rejection of 
this type involves both humoral and cellular mechanisms, the researchers injected islets and 
bone marrow in distantly related animals in hopes of controlling these mechanisms. They 
wanted to test the possibility of prolonging the life of human islets transplanted into the 
kidneys ofrats following the injection of the thymus of the rat with human bone marrow. 
This bone marrow injection is an attempt to induce tolerance of the rat to human cells. 
Since earlier studies had shown that this sort of tolerance induction to be successful in 
allograft transplantations, it was a disappointment to find that this xenograft transplant did 
not produce the same success. The treatment of the rats with human bone marrow did not 
produce a significant tolerance that was able to prolong the survival of the islet xenograft 
(Castagna 1994). Almost as important as successful trials in xenotransplantation, failures 
to lengthen life of xenografts are extremely important in furthering the understanding and 
possibilities of the mechanisms in cross-species transplantation. 
Another success story in xenotransplants is a study done with pigs and dogs. In 
this investigation, hyperacute rejection and the problem of preformed antibodies against 
donor organ antigen is further explored. The researchers attempted to remove the 
antibodies from the recipient through different means in order to study the nature of this 
hyperacute rejection. In this case, pig kidneys were transplanted into dogs. It was 
observed that having low levels of xenoantibodies led to increased survival of pig kidneys 
(Davies 1994). The removal of the anit-pig antibodies from the dog involved different 
forms of adsorption. This adsorption was done by removing plasma from the dog and 
pouring the plasma through a specific donor organ and then returning this plasma back 
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into the dog. One case of adsorption was done with pig spleen and it removed about 92% 
of the anti-pig antibodies. Adsorption was also done with pig liver. The liver was used 
because it had a greater surface area of endothelial cells. This process was successful at 
removing about 98% of the xenoantibodies. The research team went further in their 
attempt by first using the pig spleen to adsorb the anit-pig antibodies and followed it with 
another adsorption using pig liver. Again, 98% of the xenoantibodies were removed 
(Davies 1994). After the completion of the adsorption process, the pig kidneys were 
placed into the dogs and the results recorded. In the normal hyperacute rejection without 
the adsorption ofxenoantibodies, features such as vascular microthrombi, mild infiltration 
of polymorphonuclear cells, and interstitial edema was seen. After the adsorption of the 
preformed anti-pig antibodies, the features of hyperacute rejection showed no evidence of 
microthrombi, but did show tubular necrosis, interstitial edema, and infiltration of 
neutrophils (Davies 1994). In untreated dogs, there was also observed heavy deposits of 
IgG and IgM of particular patterns in the spleen. In dogs that had undergone treatment 
ofxenoantibody adsorption, the deposit ofIgG and IgM were not as heavy although the 
patterns were still the same. This study concluded that the reduction of preformed 
xenoantibodies can prolong the survival of the xenograft and it is possible to significantly 
reduce the level of xenoantibodies although not completely (Davies 1994). 
The interaction of cells between two different species has not always been studied 
for the purpose of seeking a means of prolonging the survival of an organ or tissue. In 
one study, humans and mice were used to study apoptosis and its role in fighting tumors. 
This programmed cell death is initiated by natural killer cells, T cells, and cytokines. It has 
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-been observed that an AOP-l antigen can be located on the surfaces of activated T cells 
and B cells. When the murine antibody binds to this AOP-l antigen, programmed cell 
death is activated. The presence of an anti-AOP-l antibody could playa role in the 
destruction of cells expressing this AOP-l. It was observed that the anti-AOP-l antibody 
is a mediator of cell death. Unlike complement or antibody-dependent, cell mediated 
cytoxicity, it does not require effector cells. By binding the F(ab')2 fragments of the anti-
AOP-l antibody programmed cell death was inhibited. This indicates that the anti-AOP-l 
antibody could playa role in the killing of tumor cells (Coney 1994). The combination of 
mouse and human antibodies were made of the anti-AOP-l type with the human isotype of 
IgG3 to test their effectiveness at initiating apoptosis. This chimeric antibody was seen to 
play an important part of programmed cell death of tumor cells that express the AOP-l 
antigen (Coney 1994). This research is important because the ability to produce 
antibodies for specific tumor cells could lead to needed anti-tumor reagents. This study 
showed the possibility of making an anti-AOP-l antibody that has a decreased 
immunogenicity (due to the human Fc region) but does not alter the antigen's ability to 
bind to target cells. It is also possible to cross-link this anti-AOP-l antibody with AOP-l 
antigen to cause a regression in tumors. This antibody is especially important for the fact 
that even low levels of this anti-AOP antibody can cause the regression oflarge tumors 
(Coney 1994). This study could be important in xenotransplantation in furthering the 
knowledge of chimeric molecules and their role in making an anitgen "less foreign" and 
thus less likely to cause rejection of donor tissue or organs. 
Mice have been used in many other studies in xenotransplantation. There have 
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-been several cases involving transplants between mice and rats. One important 
exploration focused on the role ofMHC class I and II molecules in the acceptance or 
rejection ofxenotransplantation. MHC molecules are key players in recognition of 
xenoantigens and induction of the activation of effector cells. A study of this role was 
done through the transplantation of liver and hearts from MHC class I and II "knock out 
mice" into rats. These donor mice had the self recognition cell surface markers removed 
before the organ was transplanted. Rat livers and hearts were also transplanted into these 
types of mice. The results of these xenotransplantation indicate that the rejection of the 
rat heart in the mouse recipient showed infiltration of mononuclear cells and heavy 
thrombosis. The mouse liver and heart in the rat revealed humoral responses were 
primarily involved in this rejection. This study suggests that the MHC class I and II 
molecules of the donor may be of little significance in the tempo of xenograft rejection 
between these two species (JJ Fung 1996). 
Another study involving rats and mice takes the previous observation concerning 
the MHC molecules and tests another mechanism effecting the tempo of xenograft 
rejection. Since the MHC class I and II "knock out" recipients showed no change in the 
tempo of rejection, direct presentation of the xenoantigen by the donor's antigen 
presenting cells were suspected. This was examined through the use of the hearts of mice 
that have been injected with the bone marrow of the recipient before being transplanted 
into rats. This was done to attempt to induce tolerance. The outcome was a slight 
increase in xenograft survival (Denetris 1996). The experimental procedure was extended 
by the addition of the drug FK 506 with the bone marrow. This showed a much more 
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-significant prolonging of heart survival. When these transplanted hearts were studied for 
the movement of cells of both the donor and recipient, the chimerism showed that 50-
90% of the ceJls were those originating from the donor. This indicates that the donor 
leukocytes may be critical in the recognition of the xenoantigen in concordant 
xenotransplantation (Denetris 1996). 
The search for successful transplantation between rats and mice continues on to 
yet another study. This one focused on the role of antibodies in the acceptance and 
rejection of xenotransplants. The key players involved are the chimeric molecule of 
CTLA4Ig and anti-CD4/CD8 antibodies. The activation ofT ceJls through the TCR is 
costimulated by the interaction ofCD28 with its B7ligand. Thirty two percent of the 
amino acids ofthe CTLA4 are identical to the CD28 and CTLA4 is a co-receptor for B7. 
The genomic organization of the two are also similar. The CTLA4Ig has been observed to 
stop the production of T cell dependent antibodies, thus preventing the activated T cell 
proliferation. Other proteins, anti-CD4 ant anti-CD8 antibodies, were used to test for 
their ability to prolong the survival ofxenotransplants. The treatment of anit-CD4/CD8 
antibodies and CTLA4Ig of the donor skin and heart before transplant was attempted 
between rats and mice. GK1.5 is the specific antibody that limits the proliferation and 
lymphokine release ofCD4. GK2.43 is the rat antibody (IgG) that targets CD8. The anti-
CD4 antibody was observed to cause the longer survival of transplanted hearts indicating 
that CD4 plays an important role in the rejection ofxenografts. Anti-CD8 appeared to 
have no effect on the xenograft rejection by itself (Flye 1996). Using these antibodies, the 
research team used different combinations to observe their effects on the rejection. The 
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-combination of GK1.5 and GK2.43 showed a prolonged survival of the transplanted 
organ. CTLA4Ig by itself also prolonged the survival and when it was combined with the 
other two antibodies the xenograft survival was significantly extended (Flye 1996). 
A study involving hamsters and rats has lead to an important growth of knowledge 
for xenotransplantation. With all the advancements made in stopping hyperacute rejection 
there is still another problem transplant specialists must face. When hyperacute rejection 
is successfully avoided, the xenograft is rejected even with the use of high levels of 
immunosuppressive drugs. This rejection is referred to as delayed xenograft rejection. 
This type of rejection involves the ineffectiveness of immunosuppressive drugs, large 
amount ofxenoantibody deposition, the infiltration of cells consisting mainly of 
macrophages. The effector cells that play critical roles in this form of rejection are a 
combination of antibodies, macrophages, and natural killer cells. Hamsters hearts were 
transplanted into rats to study this delayed xenograft rejection. Hyperacute rejection was 
inhibited by the combination of the immunosuppressive drugs ofleflunomide and 
cyclosporine and this delayed rejection was observed. When the immunosuppression was 
withdrawn, the xenograft was rejected within 6-11 days. This was paralleled with an 
increase in the number of antibodies produced and cellular movement into the donor organ 
(Chong 1996). This study showed its importance in the fact that it brought to the 
awareness of others that overcoming hyperacute rejection is only the first step in 
performing a successful xenotransplantation. 
One of the most recent as well as controversial studies that has taken place in the 
U.S. is the transplant between baboon and human at the University of California in San 
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Francisco. Knowing that baboons are resistant to the mv virus and that there have been 
no natural antibodies found in the human immune system that are specific for baboon 
antigens, transplant surgeon Suzanne Ildstad sought the approval to transplant the bone 
marrow of a baboon into a patient suffering with AIDS. Jeff Getty, the AIDS patient, 
was successfully given the baboon bone marrow in December of 1995 after a severe 
pretreatment of large doses of anti-rejection immunosuppressive drugs, chemotherapy and 
radiation. As of October of 1996 Getty seems to be healthy. His T cell count is at 75 
cells per square millimeter of blood. This is the highest his T cell count has been in four 
years and it is four times the count as when he began the transplant procedure (Benowitz 
1996). Although Getty is improving, there is no evidence that it is due to the baboon bone 
marrow. The studies are still being done to see in the bone marrow took in Getty. If the 
bone marrow took, baboon lymphocytes will be present in lymph tissue of Getty. Ildstad 
is optimistic, however, and she is already in the process of seeking approval by the FDA 
for another baboon bone marrow transplant into human with AIDS. 
In Ildstad's hope of successful xenotransplantation, she has recently moved to 
Allegheny University where she is head of the newly formed Institute for Cellular 
Therapeutics. The goal of this organization is to bring together people from all necessary 
areas of science to bring about this success. It includes transplant surgeons of organs and 
bone marrow, immunologists, and molecular and radiation biologists. Ildstad plans to 
address several issues which involve the use of bone marrow in inducing tolerance in 
xenotransplants, the use of targeted cell therapies to fight opportunistic infections, 
and to examine the use of bone marrow transplants in combating autoimmune diseases 
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-(Benowitz 1996). 
The University of Pittsburgh is another leading resource in the growing knowledge 
of transplantation. Through several extensive laboratory studies, they have determined 
four drugs that are most successful in xenotransplants involving humans. These drugs 
include cyclophosphamide, FK506, prednisone, and prostaglandin E (Rossi 1996). 
Cyclophosphamide is a chemical substance that prohibits the proliferation ofB cells. The 
function ofFK506 is to interfere with and inhibit the T cell of the recipient from 
destroying the donor organ. The steroid hormone prednisone plays a role in inhibiting the 
activity of antigen presenting cells and prostaglandin E manipulates cytokines and other 
cell that induce inflammation. 
With all of these advancements in xenotransplantation, there are many people who 
are against the furthering of this research for several reasons. Their biggest and most 
compelling argument is the possibility of animal viruses infecting humans. With the 
unpredictable mutations of viruses and the ability of these viruses to recombine with other 
pathogens, dangerous new diseases could arise. The recipient of the animal organ donor 
would be at high risk because their bodies would not be able to fight these new pathogens 
due to the high doses of immunosuppressive drugs that the patient would be given to help 
them to prevent rejection of the donor organ. This infectious virus could even possibly be 
passed on to all of the people who come in contact with the xenotransplant recipient. This 
could possibly lead to a pandemic that could reach the entire globe (Koechlin 1996). 
There have been several cases of such animal viruses causing severe illnesses and even 
death in the human population. In 1967 there was an importation of monkeys into 
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Germany that were infected with Marburg filovirus. This virus found hosts in humans and 
31 people were infected and 23% of those infected died. Sudan (in 1976) and Zaire (in 
1976, 1979, and 1995) both experienced such a virus, the Ebola filovirus, that had a case 
fatality rate of 80-90%. The Crimean-Congo hemorrhagic fever virus jumped from a goat 
to humans in Pakistan in 1976. This virus infected 17 people with a fatality of24%. 
Another important case which involves mv is one of speculation. The mv viruses type 
1 and 2 are suspected to have originated from a monkey that passed the virus to humans 
(Koechlin 1996). 
Another argument for the opposition to xenotransplantation is the fact that the 
risks ofthis form of transplantation is largely unknown. "Too little of the science behind 
the experiment is understood," said virologist Jonathan Allen in his skepticism of this type 
of transplantation. Others are arguing the fact that even with carefully designed tests, 
there cannot be a test to screen for something that is unknown (Hanson 1996). The 
unknowns can also expand into the effect that these animal cells would have in the human 
body and most importantly to the human mind. With part of the body of human origin 
while other parts of another animal origin, it could change world's ideas of what it is to be 
human (Koechlin 1996). There is a possibility that xenotransplantation could affect the 
recipient's identity and sense of self 
The research scientists behind these studies as well as others are quick to the 
defense ofxenotransplantation. They do not feel that the risk to an infectious disease 
being transmitted between animal and human is a very large risk. The Secretary General 
of a Swiss pharmaceutical lobby group, Thomas Cueni, believes that there is only an 
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extremely small chance of finding pig viruses that would be dangerous to humans 
(Koechlin 1996). In rebuttal to the fear of mutations and recombinations of viruses, it was 
said at the Institute of Medicine conference in June of 1995 that these researchers "are 
doing nothing different from what is already occurring in nature. In fact, nature is more 
dangerous because the genetic mutations occurring in nature are not controlled, as they 
are in the lab." With the careful controls of the laboratory this procedure could be 
eliminated of many of the risks of concern. In response to the human identity being lost, 
xenotransplant advocates feel that this would not be an issue. The humanity of the 
recipient is protected by the blood-brain barrier which would not allow the animal cells to 
cross over into the brain. 
One of the biggest arguments in support of xenotransplantation is the indisputable 
need for organs. As mentioned before, approximately 33,000 patients are on the waiting 
list for an organ and its is expected that nearly half of them will die before a proper organ 
is found for them. Not only are solid organs in need, but so are tissues and cells. One 
million people in America will die of AIDS in the next seven years. The possibilities of 
Ildstad's baboon bone marrow in human AIDS patient study could save many lives. 
Jeffrey Platt of Duke University supports xenotransplantation on the base of need by 
saying that with the shortage of organs and the tremendous clinical need for them, the 
medical profession has the ability to help those in need but not enough organs. 
Xenotransplants could give the organs needed to save thousands of lives. 
The fact that using animals to successfully aid humans has already being done is 
another compelling argument for the pro-xenotransplant side. There are many instances 
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everyday in which biological material is taken from animals and is placed in humans. Such 
examples include the use of fetal calf serum, calf serum, and horse serum that are used in 
cell cultures to produce vaccines used for humans. Porcine skin has been used to repair 
burns on human bodies. Pigs have also contributed insulin and heart valves to save human 
lives. There may be little to no difference between xenotransplantation and the use of 
these biological materials that have not been sterilized (Murphy 1996). 
At a conference held in July of 1996 the Institute of Medicine of the United States 
and the Nuffield Council on Bioethics of the United Kingdom both came to the same 
conclusion of supporting the future research and trials ofxenotransplantation. They each 
made strong arguments that the probable benefits that could be gained from this type of 
transplantation outweighs the possible risks that are involved (Marwick 1996). The 
Nuffield Council reported that "it would be unacceptably conservative to prohibit an 
innovation on the grounds oftransrnitting possible viruses." The Institute of Medicine 
stated that "as members of society we can't run away from the risks that may be involved 
in helping those in need." With the thousands in need and the shortage of human donors, 
something needs to be done and xenotransplantation may be the best option. 
Even though the Institute of Medicine has given the go ahead to further proceed in 
the direction of animal-to-human transplant, caution was of major concern. The issues of 
importance included regulations on animals and procedures being used as well as specific 
guidelines to inform patients, the public, and other professional involved. In August of 
1996 the American Society of Transplant Physicians issued the guidelines set forth by the 
Public Health Service that are to be followed in the case of transplanting animal organs or 
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tissue into humans. The Draft Public Health Service Guideline on Infectious Disease 
Issues in Xenotransplantations focuses on four specific concerns. These concerns include 
the clinical issues, animal issues, recipient issues, and record keeping issues. The role of 
this draft is to help reduce public health risks that are connected with xenotransplantation 
without limiting the availability of promising treatments for those with a life-threatening 
illness. 
The clinical plan is the first section of these guidelines. It involves several 
regulations that are to be followed concerning the clinical center. The professional team 
participating in the xenotransplant should include a surgeon, an infectious disease 
physician, a veterinarian, a transplant immunologist, an infection control specialist, and a 
clinical microbiologist. The facility should have an accredited microbiology and virology 
laboratories. The center should have a Biosafety Committee that reviews each protocol 
which will also be looked over by the Institutional Animal Care and Use Committee, the 
Institutional Review Board and FDA. This protocol should clearly state the types of 
screening methods that will be used as well as revealing the potential risks to the patient 
and those in close contact of the patient. 
The concern of the animals and their sources are addressed in the second section. 
The donors animals should be taken only from well screened and closed herds. These 
colonies must be carefully characterized and protected against as many potential agents 
that may cause infections as possible which means that all animals are to be bred and 
raised in captivity. There should also be accurate and specific records made of the lineage 
all animals. 
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-The issues surrounding the recipient and clinical staff are also important. Several 
of the highlights of these regulations are as follows. The condition of the patient's health 
is to be monitored not only clinically but also through specific tests run in the laboratory. 
These lab tests must be determined and carefully recorded before the transplant takes 
place. The recipients of these animal donors must be informed of the possible risks to 
themselves as well to close contacts. These close contacts should also be educated of the 
risks involved as well as the health care team participating in the monitoring of the 
recipient. Laboratories of the facility must be available to culture and identify agents that 
could cause infection. Samples of each patient's serum is to be collected and stored for 
future reference. Careful records must be maintained and must be done in a manner that 
protects the confidentiality of every patient. 
The final section of the guidelines address public health needs. A proposal is 
made for a national registry. This would aid in the identification of health problems that 
are concerns of the public that are associated with xenotransplantation. Communication is 
the key factor in these regulations set up by Public Health Service. The FDA is to playa 
role in the design of this registry. They are also responsible for providing the framework 
of the regulations on these new biological experiments. The protocols for each 
xenotransplant must follow the guidelines of the Investigational New Drug application and 
must be filed with the FDA for approval. 
Although xenotransplantation has not been completely mastered by scientists 
today, it is advancing quickly and shows a promising future in saving tens of thousands 
and maybe even millions of lives. There are many unknown factors that are playing a 
20 
-critical role in the concerns of people nation wide. The past three years have shown a 
tremendous leap in knowledge and a large number on the unknowns are becoming known. 
Science cannot be afraid of the risks involved in this opportunity but they should be 
cautious of the risks involved, careful with their strategies, and open in communication 
with others so that everyone can be well informed of the progress and the risks. In the 
words of Thomas Starzl, " science has progressed far enough that real lives hang in the 
balance, not to pursue further progress would clearly be unjustifiable" (Hanson 1995). 
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